Top

Published in:

01-12-2005 | Gastrointestinal

Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI

Authors: Christian Stroszczynski, Dominik Jost, Peter Reichardt, Petra Chmelik, Gunnar Gaffke, Albrecht Kretzschmar, Ulrike Schneider, Roland Felix, Peter Hohenberger

Published in: European Radiology | Issue 12/2005

Abstract

Typical MRI findings for gastro-intestinal stromal tumours (GIST) under treatment with imatinib were evaluated. MRI was performed in 45 patients (25 responders, 20 non-responders) with metastatic or locally advanced, unresectable GIST. Target lesions were selected and re-evaluated after 2, 4, and 6 months of therapy with imatinib. The target tumour response (TTR) was classified according to RECIST criteria. TTR, signal intensity in the centre and border of the lesion and the presence and the extension of a hypervascular rim were analysed. The mean diameter of the marker lesions decreased significantly (P<0.001) from 7.1±2.6 cm to 5.9±2.3 cm after 6 months. Accuracy of RECIST criteria was 51%, 69% and 73% on MRI 2, 4 and 6 months for response assessment. In addition, responders had higher signal-to-noise ratios on T2-w images after 2 months (P<0.05) and a decrease of vascularised areas in the lesion 4 and 6 months after treatment (each P<0.01), when compared with non-responders. Beyond the size measurement for response assessment, MRI provides additional information of tumour response using SI of T2-w images and quantification of vascularised areas of GIST manifestations.

Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U, Wangberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 89:460–464PubMed

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D (2005) Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 9:1–142

Shojaku H, Futatsuya R, Seto H, Tajika S, Matsunou H (1997) Malignant gastrointestinal stromal tumor of the small intestine: radiologic-pathologic correlation. Radiat Med 15:189–192PubMed

Maki RG (2004) Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. Curr Treat Options Gastroenterol 7:13–17PubMed

Joensuu H, Roberts PJ, Sarlomo Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMed

Joensuu H, Dimitrijevic S (2001) Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33:451–455PubMed

van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS (2002) European organisation for research and treatment of cancer soft tissue and bone sarcoma group. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft tissue and bone sarcoma group. Eur J Cancer 38 Suppl 5:S83–S87PubMed

Andersson J, Sjogren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG (2002) The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160:15–22PubMed

Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC (2003) Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 226:527–532PubMed

10.

Ghanem N, Altehoefer C, Furtwangler A, Winterer J, Schafer O, Springer O, Kotter E, Langer M (2003) Computed tomography in gastrointestinal stromal tumors. Eur Radiol 13:1669–1678PubMed

11.

Kim HC, Lee JM, Kim KW, Park SH, Kim SH, Lee JY, Han JK, Choi BI (2004) Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy. AJR Am J Roentgenol 183:893–898PubMed

12.

Tateishi U, Hasegawa T, Satake M, Moriyama N (2003) Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality. J Comput Assist Tomogr 27:792–798PubMed

13.

Chen MYM, Bechtold RE, Savage PD (2002) Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 179:1059–1062PubMed

14.

Sigmund G, Buitrago-Tellez CH, Torhorst J, Steinbrich W (2000) Radiology of gastrointestinal stromal tumors (GIST) and a case of carney syndrome. Fortschr Rontgenstr 172:287–294CrossRef

15.

Tervahartiala P, Halavaara J (1998) Radiology of GIST. Gastrointestinal stromal tumours. Ann Chir Gynaecol 87:291–292PubMed

16.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMed

17.

Hasegawa S, Semelka RC, Noone TC, Woosley JT, Marcos HB, Kenney PJ, Siegelman ES (1998) Gastric stromal sarcomas: correlation of MR imaging and histopathologic findings in nine patients. Radiology 208:591–595PubMed

18.

Reichardt P, Schneider U, Stroszczynski C, Pink D, Hohenberger P (2004) Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol 57:215–217CrossRefPubMed

19.

Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5:S60–S65

20.

Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:3357–3365

21.

Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D (2004) The role of (18)F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21PubMed

22.

Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020CrossRefPubMed

23.

Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655–664PubMed

24.

Jost D, Stroszczynski C, Chmelik P, Gaffke G, Schlecht I, Pink D, Reichardt P, Schneider U, Hohenberger P, Felix R (2003) Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib. Fortschr Rontgenstr 175:791–798CrossRef

25.

van den Abbeele AD, Badawi RD, Cliche JP et al (2002) Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT [abstract]. Radiology 225 (Suppl):424

Title: Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI
Authors: Christian Stroszczynski
Dominik Jost
Peter Reichardt
Petra Chmelik
Gunnar Gaffke
Albrecht Kretzschmar
Ulrike Schneider
Roland Felix
Peter Hohenberger
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: European Radiology / Issue 12/2005
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-005-2867-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2005

Psychophysical analysis of monitor display functions affecting observer diagnostic performance of CT image on liquid crystal display monitors

Magnetic resonance imaging of shoulders with idiopathic adhesive capsulitis: reliability of measures

Comprehensive MR angiography of the lower limbs: a hybrid dual-bolus approach including the pedal arteries

An unusual cause for dysphagia (2005: 12a)

Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma

Imaging of penile traumas—therapeutic implications